Your browser doesn't support javascript.
loading
Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer.
Panella, Riccardo; Cotton, Cody A; Maymi, Valerie A; Best, Sachem; Berry, Kelsey E; Lee, Samuel; Batalini, Felipe; Vlachos, Ioannis S; Clohessy, John G; Kauppinen, Sakari; Pandolfi, Pier Paolo.
Afiliación
  • Panella R; Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Cotton CA; Center for Genomic Medicine, Desert Research Institute, Reno, NV 89512, USA.
  • Maymi VA; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, 2450 Copenhagen, Denmark.
  • Best S; Center for Genomic Medicine, Desert Research Institute, Reno, NV 89512, USA.
  • Berry KE; Preclinical Murine Pharmacogenetics Facility and Mouse Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Lee S; Preclinical Murine Pharmacogenetics Facility and Mouse Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Batalini F; Center for Genomic Medicine, Desert Research Institute, Reno, NV 89512, USA.
  • Vlachos IS; Preclinical Murine Pharmacogenetics Facility and Mouse Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Clohessy JG; Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Kauppinen S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Pandolfi PP; Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Biomedicines ; 11(5)2023 05 18.
Article en En | MEDLINE | ID: mdl-37239141
ABSTRACT
microRNA-22 (miR-22) is an oncogenic miRNA whose up-regulation promotes epithelial-mesenchymal transition (EMT), tumor invasion, and metastasis in hormone-responsive breast cancer. Here we show that miR-22 plays a key role in triple negative breast cancer (TNBC) by promoting EMT and aggressiveness in 2D and 3D cell models and a mouse xenograft model of human TNBC, respectively. Furthermore, we report that miR-22 inhibition using an LNA-modified antimiR-22 compound is effective in reducing EMT both in vitro and in vivo. Importantly, pharmacologic inhibition of miR-22 suppressed metastatic spread and markedly prolonged survival in mouse xenograft models of metastatic TNBC highlighting the potential of miR-22 silencing as a new therapeutic strategy for the treatment of TNBC.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos